Author Archives for: Jesse Spacco

American Society of Clinical Oncology

Developing Targeted and Immune Therapies for Colorectal Cancer Molecular Subtypes Wafik El-Deiry, MD, PhD, FACP, and colleagues from Fox Chase Cancer Center recently collaborated with Caris Life Sciences®, a biotechnology company headquartered in Dallas-Fort Worth, Texas, to conduct three separate studies related to precision medicine, particularly in colorectal cancers. The findings were highlighted at the 2015 ASCO Annual Meeting. “There is exciting progress in the treatment of colorectal cancer. Understanding the impact of genetic mutations on the potential likelihood of response to new treatments helps pave the way for defining their optimal use,” says El-Deiry, deputy cancer center director for … Continue Reading »

Small-Molecule Compound Shows Promise for Treating Drug-Resistant Tumors

spheres-1-revA new compound called ONC201/TIC10 has entered clinical trials and may have the potential to treat various forms of drug-resistant cancers. Through a screen of an NCI chemical library, Wafik S. El-Deiry, MD, PhD, FACP, professor of medical oncology and deputy director for translational research at Fox Chase Cancer Center, and his colleagues discovered ONC201/TIC10. Continue Reading »

Sigurdson Elected to SSO Executive Council

Fox Chase Cancer Center surgeon Elin Sigurdson, MD, PhD, FACS, has been elected to the Executive Council of the Society of Surgical Oncology (SSO) for a three-year term. The council, which consists of 18 members, acts as the governing body and Board of Directors for the SSO, guiding the Society’s strategic direction and managing its affairs. Founded in 1940 as the James Ewing Society, the SSO marks its 75th anniversary this year as the premier organization for surgeons and health care providers dedicated to advancing and promoting the science, education, and practice of cancer surgery worldwide. The 2,800-member Society’s focus … Continue Reading »

Beck Receives Cancer Control Award

J. Robert Beck, MD, senior vice president, deputy director, chief academic officer, chief administrative officer, and H.O. West and J.R. Wike Chair in Cancer Research at Fox Chase, received the 2014 Cancer Control Award. The award celebrates the spirit of volunteerism and work that advances cancer research, patient care, and advocacy. Beck oversees all activities that support Fox Chase’s academic and research operations. He also maintains research interests in technology assessment, cost-effectiveness of cancer therapies, cancer health disparities, and the organization of biomedical informatics services and general academic resources.

Comments Off

Fox Chase Recognized for Commitment to ACS

Fox Chase Cancer Center was honored with the Partners in Health Initiatives Award for its high level of commitment to the mission of ACS. The award is given to organizations that have demonstrated outstanding efforts to link ACS goals and priorities with the goals and priorities of the system that they represent.

Comments Off

Pancreatic Cancer Cells Hijack Vitamin D Receptor in Fight Against Chemotherapy

The Topline  Pancreatic cancer cells use the vitamin D receptor (VDR) to repair the damage caused by gemcitabine Treatments that inhibit VDR may render tumors more sensitive to cancer-killing drugs VDR appears to act epigenetically on RAD51 to fix DNA damage caused by chemotherapy and allow tumor cells to survive and continue dividing Pancreatic cancer is one of the deadliest forms of the disease. Doctors’ typical line of attack involves DNA-damaging agents such as gemcitabine, but despite the potent activities of these drugs, patient survival is only extended by a few months, if that. Indeed, pancreatic cancer has the lowest … Continue Reading »

Comments Off

Fusion Biopsy Improves Detection of Prostate Cancer

The TopLine Fusion-guided biopsy combines MR images with real-time ultrasound images to create a better target for the biopsy The technology can help lower the risk of missing aggressive tumors and can avoid future unnecessary biopsies An innovative technology called MR/ultrasound fusion prostate biopsy is allowing Fox Chase physicians to take a much more targeted approach to the collection of tissue samples from patients undergoing prostate biopsies. Currently, patients with low-risk prostate cancer often choose a strategy of active surveillance, the recommended course to avoid overtreatment. Yet there is a risk of disease progression, especially if the cancer is more … Continue Reading »

Comments Off